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Background: The ongoing “Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment stra-
tegies (SPRINTT)” randomized controlled trial (RCT) is testing the efficacy of a multicomponent intervention in
the prevention of mobility disability in older adults with physical frailty & sarcopenia (PF&S). Here, we describe
the procedures followed for PF&S case finding and screening of candidate participants for the SPRINTT RCT. We
also illustrate the main demographic and clinical characteristics of eligible screenees.
Methods: The identification of PF&S was based on the co-occurrence of three defining elements: (1) reduced
physical performance (defined as a score on the Short Physical Performance Battery between 3 and 9); (2) low
muscle mass according to the criteria released by the Foundation for the National Institutes of Health; and (3)
absence of mobility disability (defined as ability to complete the 400-m walk test in 15min). SPRINTT was
advertised through a variety of means. Site-specific case finding strategies were developed to accommodate the
variability across centers in catchment area characteristics and access to the target population. A quick “parti-
cipant profiling” questionnaire was devised to facilitate PF&S case finding.
Results: During approximately 22months, 12,358 prescreening interviews were completed in 17 SPRINTT sites
resulting in 6710 clinic screening visits. Eventually, 1566 candidates were found to be eligible for participating
in the SPRINTT RCT. Eligible screenees showed substantial physical function impairment and comorbidity
burden. In most centers, project advertisement through mass media was the most rewarding case finding
strategy.
Conclusion: PF&S case finding in the community is a challenging, but feasible task. Although largely autonomous
in daily life activities, older adults with PF&S suffer from significant functional impairment and comorbidity.
This subset of the older population is therefore at high risk for disability and other negative health-related
events. Key strategies to consider for successfully intercepting at-risk older adults should focus on mass com-
munication methods.
1. Introduction
The last decade has witnessed the proliferation of research programs
aimed at testing interventions to foster independence in older adults by
targeting functional impairment rather than individual diseases
(Beswick et al., 2008; Puts et al., 2017). This approach is not a “be-
trayal” of the noble mission of medicine of reducing mortality and
promoting healthiness. Indeed, functional status is the single most im-
portant measure of health in older persons, being a major determinant
of well-being and survival (Studenski et al., 2011; Steptoe et al., 2015;
Cesari et al., 2016; Landi et al., 2016). The “Lifestyle Interventions and
Independence for Elders” (LIFE) study (Pahor et al., 2014) and the
“Multi-modal Intervention in Diabetes in Frailty” (MID-Frail) study
(Rodríguez-Mañas et al., 2014) have been the most notable initiatives
in the field. The randomized controlled trial (RCT) conducted as part of
the “Sarcopenia and Physical fRailty IN older people: multi-componenT
Treatment strategies” (SPRINTT) project was conceived as an evolution
of the pioneering LIFE study (Marzetti et al., 2015; Landi et al., 2017).
The project is funded by the Innovative Medicines Initiative (IMI), a
public-private partnership between the European Union and the Eur-
opean Federation of Pharmaceutical Industries and Associations
(EFPIA). The agency is strategically equipped to foster the research in
areas where there is an unmet medical or social need by supporting
collaborative efforts of academic and industrial partners.
Similar to LIFE, in SPRINTT, candidate participants are considered
to be eligible if presenting with functional limitations in the absence of
mobility disability (Pahor et al., 2014; Landi et al., 2017). In SPRINTT,
however, the functional impairment needs to be associated with low
appendicular lean mass (aLM). This combination identifies a novel
condition, termed physical frailty & sarcopenia (PF&S) (Cesari et al.,
2017), in which muscle atrophy is envisioned as the biological sub-
stratum of physical frailty (Landi et al., 2015). Notably, at the end of an
ad hoc scientific advisory procedure, PF&S has received initial en-
dorsement by the European Medicines Agency (EMA) as a prototypical
geriatric pre-disability condition.
The other major difference from LIFE is the nature of intervention
administered to the active group. While LIFE adopted a unidimensional
intervention (i.e., physical activity) to prevent the outcome of interest,
SPRINTT participants receive a personalized combination of physical
activity, nutritional counseling/dietary intervention, and an informa-
tion & communication technology (ICT) intervention (Landi et al.,
2017). The rationale underlying the multicomponent intervention
(MCI) chosen in SPRINTT resides in the proposition that the complex
framework within which PF&S develops may be more efficiently
tackled through a multidomain, person-tailored intervention (Beswick
et al., 2008; Cesari et al., 2017).
Here, we illustrate the procedures for PF&S case finding and
screening of candidate SPRINTT RCT participants. The main demo-
graphic and clinical characteristics of older adults with PF&S who were
found to be eligible for participating in the RCT are also described.
2. Methods
2.1. Overview
The SPRINTT trial is a phase III, single-blind, multicenter RCT
(ClinicalTrials.gov identifier: NCT02582138) that is being conducted to
compare the efficacy of a MCI program (i.e., physical activity, nutri-
tional counseling/dietary intervention, and ICT intervention) versus a
healthy aging lifestyle education (HALE) program for preventing mo-
bility disability in older persons with PF&S. The MCI and the HALE
intervention are thoroughly described elsewhere (Landi et al., 2017;
Marzetti et al., 2017). Like in LIFE (Pahor et al., 2014), the primary
outcome of mobility disability has been operationalized as incident
inability to complete the 400-m walk test (Simonsick et al., 2001).
Secondary outcomes of SPRINTT are detailed elsewhere (Landi et al.,
2017).
The SPRINTT RCT is currently being conducted in 16 sites, located
in 11 European countries, under the coordination of the Department of
Geriatrics at the Università Cattolica del Sacro Cuore (Rome, Italy)
(Table 1). As discussed later, one clinical site withdrew from the study
during the recruitment phase. Trial operations are also supported by
members of EFPIA (Sanofi-Aventis R&D, Novartis, GlaxoSmithKline,
Servier, Astellas, Biophytis, and Boehringer-Ingelheim).
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2.2. Strategies for PF&S case finding
Study sites were allowed to develop their own recruitment plan to
accommodate the variability of catchment area characteristics and ac-
cess to the target population across the multiple European centers. In
general, case finding strategies included the use of newspapers, radio
and television advertisements, direct mails, and direct approach by
trained personnel at health fairs, supermarkets, pharmacies, senior
centers, medical clinics, civic organizations, and churches. Participants
in previous studies were approached, and ineligible candidates asked
for relatives or friends who might have been eligible. Special attention
was paid to informing healthcare providers (in particular, general
practitioners, physiotherapists, nurses, and pharmacists), medical
clinics, and hospitals within the catching area of each center about the
SPRINTT trial. Advertisement material, including brochures and pos-
ters, was distributed in malls, grocery stores, hobby shops, public li-
braries, pharmacies, post offices, train stations, etc. Direct mailing
campaigns were also used to distribute study brochures and in-
troductory letters to specific geographic areas. Telephone or in-person
contacts with healthcare providers were established to seek for their
assistance in recruiting older persons for the study. Early on, a dedi-
cated website (www.mysprintt.eu) was created to promote awareness
of the project among the general public as well as healthcare profes-
sionals and researchers and to foster recruitment. The study was also
advertised through various older persons' organizations (e.g., retired
persons' trade unions, local senior groups and third age universities). In
Italy, a formal collaboration was established with Coldiretti, the largest
organization of farmers at national and European level, to promote the
participation in the trial among its members. Finally, a quick “partici-
pant profiling” questionnaire [the so-called “Frailty Bureau of
Investigation” (FBI) questionnaire] was developed and distributed to
the staff in charge of participant recruitment across SPRINTT centers
(Fig. 1).
A centralized monitoring team (CMT) was appointed by the co-
ordinating center to track the various strategies and identify those that
were most successful at individual sites. To this aim, recruitment re-
ports, containing data on the number of candidates screened from the
Table 1
SPRINTT study sites.
Site name City, country
Università Cattolica del Sacro Cuore
(coordinating center)
Rome, Italy
IRCCS INRCA Ancona, Italy
University of Parma Parma, Italy
University Hospital of Getafe Getafe, Spain
University Hospital Ramón y Cajal Madrid, Spain
University Hospital of Toulouse Toulouse, France
University Hospital of Limoges Limoges, France
Charles University Prague, Czech Republic
Silesians Hospital Opava, Czech Republic
Jagiellonian University Medical College Krakow, Poland
Friedrich-Alexander Universität Erlangen-
Nürnberg
Nurnberg, Germany
Maastricht University Medical Center Maastricht, The Netherlands
University of Helsinki Helsinki, Finland
Diabetes Frail, Medici Medical Practice Luton, United Kingdom
Aston University of Birminghama Birmingham, United Kingdom
Medical University of Graz Graz, Austria
Lanspitali University Hospital Reykjavik, Iceland
a This site is no longer active.
Fig. 1. FBI (Frailty Bureau of Investigation) questionnaire for quick SPRINTT participant profiling.
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various case finding sources, were prepared by each clinical site and
regularly forwarded to the CMT. The information was subsequently
shared among the study sites, so that each of them could be informed on
methods that were most successful and which were not worth pursuing.
The CMT also provided assistive responses in case of difficulties
with PF&S case finding. Corrective actions were based on the recruit-
ment shortfall and tailored to the needs of the site. Teleconferences and
on-site visits were organized to discuss the reasons for the shortfall, and
to implement problem-solving methods with the aim of increasing the
number of eligible participants in the following month. In selected
cases, the CMT cooperated with local staff members in the development
of targeted strategies aimed at improving recruitment yields depending
on where individuals were lost during the case finding process.
2.3. Goals and time-frame of PF&S case finding
The identification of PF&S was based on the co-occurrence of three
defining elements: (1) reduced physical performance; (2) low muscle
mass; and (3) absence of mobility disability (i.e., ability to complete the
400-m walk test). The rationale behind each of the defining elements is
provided elsewhere (Cesari et al., 2017). Briefly, the physical frailty
domain of PF&S was based on a Short Physical Performance Battery
(SPPB) (Guralnik et al., 1994) summary score ≥3 and ≤9. By con-
vention, an older person with an SPPB score> 9 is considered to be
robust (Studenski et al., 2003). On the other hand, a score ≤9 identifies
frail individuals and a score ≤7 is commonly used to define a subgroup
of frail older adults at especially high risk of adverse events
(Vasunilashorn et al., 2009). The exclusion of individuals with SPPB
scores< 3 is motivated by the fact that such a poor performance is, in
general, not compatible with the ability to complete the 400-m walk
test (primary endpoint in the SPRINTT RCT) (Vasunilashorn et al.,
2009).
The identification of the sarcopenia component of PF&S (i.e., low
muscle mass) relied on the cut-points for aLM recommended by the
Foundation for the National Institutes of Health (FNIH) sarcopenia
project (Studenski et al., 2014). Whole-body dual energy X-ray ab-
sorptiometry (DXA) scans were used to estimate aLM, and each candi-
date participant was considered eligible if presenting an aLM-to-body
mass index (BMI) ratio (aLMBMI) below<0.789 or< 0.512 in men and
women, respectively. When the aLMBMI criterion was not met, candi-
dates were tested with the alternative criterion (i.e., crude aLM<
19.75 kg in men and< 15.02 kg in women). Different to what is
commonly done during sarcopenia assessment, no specific measures of
muscle strength (e.g., handgrip strength) were obtained. The functional
domain of sarcopenia was instead captured through the SPPB. How-
ever, handgrip strength is measured at the first visit after participant
randomization and at all subsequent visits to further assess the impact
of the MCI on muscle function.
Consistent with the LIFE RCT (Pahor et al., 2014), SPRINTT adopted
incident incapacity to complete the 400-m walk test as the primary
outcome. As such, participants were required to complete a 400-m walk
within 15min at the screening visit. This test was chosen for several
reasons: (1) it is designed to provide a dichotomous result (i.e., capa-
city/incapacity to complete the task) on the specific and meaningful
condition of mobility disability; (2) mobility disability has been in-
dicated as the first clinically relevant step of the disabling process
(Cesari et al., 2017), therefore representing a target condition of special
interest for preventive interventions; (3) the 400-m walk test is not
supposed to challenge the cardiorespiratory reserve of the individual
(as, for example, the 6-min walk test), but measures his/her capacity to
cover within a reasonable amount of time the distance required to re-
main independent in daily living (Rolland et al., 2004).
The other inclusion and exclusion criteria are detailed elsewhere
(Landi et al., 2017). Briefly, a set of eligibility criteria was devised in
order to select a population that would be: (1) at high risk of experi-
encing the mobility disability outcome during the 3-year RCT time-
frame, (2) most likely to benefit from the MCI, and (3) most likely to
comply with the intervention and assessment protocols. The age group
was selected because persons aged 70 years and older are at increased
risk of mobility disability, and are expected to have a sufficiently long
life expectancy to justify participation in a 3-year preventive trial
(Ferrucci et al., 2000). In addition, candidate participants needed to
have sufficient cognitive abilities to both provide informed consent to
the study and participate in the trial interventions. Cognitive function
was measured using the Mini Mental State Examination test (MMSE)
(Folstein et al., 1975) and those scoring<24 were considered in-
eligible for the RCT. The evaluation of nutritional status was not ob-
tained for participant selection. This parameter was assessed after the
establishment of eligibility to properly design the dietary intervention
in the MCI group.
As previously specified (Landi et al., 2017), the SPRINTT RCT aimed
at recruiting a total of 1500 70+ year-old persons with PF&S, 80% of
whom presenting with an SPPB score< 8, and the remaining 20% with
SPPB ≥8. Efforts were made to maintain these proportions at each
study site.
2.4. Screening of PF&S
The screening process for the identification of PF&S comprised five
primary components: phone screen, SPPB, health screen, 400-m walk
test, and DXA. These components were administered over two or three
contacts, i.e., a phone interview (prescreening interview) and one or
two clinic visits.
As already implemented in LIFE, before candidate participants were
invited to attend the study site for the screening visit, a number of
eligibility items were checked over the phone. This preliminary inter-
view was a quick and inexpensive method to identify potential parti-
cipants who had a high probability of being found ineligible at the
screening visit. Candidates who remained eligible were subsequently
invited to the clinical trial site to complete a screening visit and de-
termine the final eligibility. The screening process could be stopped at
any time if an eligibility criterion was not met. Based on the experience
of LIFE, it was anticipated that the SPPB would exclude a large share of
potential participants. Hence, in order to improve time- and cost-effi-
ciency of the screening process, physical performance assessment was
usually completed as the first step during the screening visit. DXA, in-
stead, was generally performed as the last assessment in order to
minimize the number of scans leading to negative results.
2.5. Training of SPRINTT staff
At each study site, staff members were requested to become familiar
with their assigned activities in order to meet high quality standards.
Before study commencement, key study staff at each site was trained
on-site by an ad hoc established standardization team (ST), whose
members were originally trained by the LIFE study staff at the
University of Florida. A train-the-trainer model was adopted, such that
staff members who were trained by the ST became then responsible for
training and re-training other staff members. As needed, the ST pro-
vided remote or on-site support for the whole duration of participant
accrual.
2.6. Statistical analysis
Descriptive statistics were used to provide the main characteristics
of screenees eligible to participating in the SPRINTT RCT. Analyses
were computed using the SAS software (version V9.4, SAS Institute,
Cary, NC).
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3. Results
3.1. Results of PF&S case finding
Case finding activities were completed in approximately 22months.
The first prescreening was conducted on January 11th 2016, whereas
the last screening was completed on October 31st 2017. Project ad-
vertisement through mass communication media was generally the
most rewarding strategy for PF&S case finding with the exception of the
site in Helsinki. Indeed, the Finnish center relied mostly on a national
registry-based method to reach out the target population. In the other
countries, depending on the study site, 60–70% of eligible enrollees
were gathered through TV, radio and newspaper ads. The remaining
candidates were retrieved via mass mailing, presentations at senior
centers, supermarkets and universities of the third age, brochures,
flyers and posters placed in patient waiting areas and primary care
physicians' offices, and word of mouth.
The flow of PF&S case finding, from the prescreening interview to
final eligibility establishment, is shown in Fig. 2. Overall, 12,358 pre-
screening interviews were completed, and 6710 candidates proceeded
to the screening visit. At the end of the process, 1566 participants were
found eligible for the RCT, 341 (21.8%) with SPPB 8-9 and 1225
(78.2%) with SPPB 3-7. The target of 1500 participants was exceeded
because some prescreened candidates whose screening visits were
scheduled after the accomplishment of the recruitment target were
eventually found to be eligible.
As depicted in Fig. 2, the main reason for screening failure was SPPB
out of range, followed by normal muscle mass at DXA, medical condi-
tions, and inability to complete the 400-m walk test. Less frequently,
candidate participants disqualified because of safety concerns during
functional testing, poor cognition (i.e., MMSE<24), behavioral con-
ditions (e.g., excessive alcohol consumption), nursing home residence,
sensory impairments, use of drugs not permitted by the protocol (e.g.,
systemic corticosteroids, androgens, estrogens, growth hormone), or
other conditions (e.g., participation in another clinical trial, physical
activity program, or physiotherapy/cardiorespiratory rehabilitation;
investigator judgment of non-safety/non-compliance).
Fig. 3 shows candidate screening and the accrual of eligible parti-
cipants during the 22-month case finding period. According to one of
the recruitment scenarios envisioned during the RCT planning phase
(Landi et al., 2017), participant enrolment exceeded the expected goal
during the first 12months and lagged behind thereafter. The delay was
due to the withdrawal of one clinical site (i.e., Aston University of
Birmingham) because of administrative issues and the slower recruit-
ment pace in other centers. In order to ensure the accomplishment of
the recruitment goal and preserve the RCT integrity, the CMT and the
project leadership engaged three backup clinical sites (i.e., Graz,
Parma, and Reykjavik), increased the case finding target in the best-
recruiting centers, and extended the accrual phase duration. The length
of participant follow-up will be maintained as planned by proportion-
ally extending the RCT operations beyond the projected closing date.
3.2. PF&S case finding across study sites
PF&S case finding was pursued in 17 clinical sites across 11
European countries (Table 1). As previously mentioned, Aston Uni-
versity of Birmingham withdrew from the study because of adminis-
trative issues after approximately 5months. The number of screenings
ranged from 33 in Birmingham to 1236 in Rome (Italy), whereas the
number of candidates with PF&S varied from 10 in Birmingham to 224
in Rome (Fig. 4). As a whole, 4.3 people were screened for every eli-
gible participant. The number of screenings per eligible candidate
ranged from 2.2 in Opava to 9.2 in Krakow (Poland) (Table 2). This
large variability was due to several factors, including differential
Fig. 2. Flow-chart of the PF&S case finding process.
For ineligible screenees, the sum of individual items
is higher than 100% because in some instances the
screening process was not stopped at the first unmet
eligibility criterion. *Includes: participation in an-
other clinical trial, physical activity program, or
physiotherapy/cardiorespiratory rehabilitation; in-
vestigator judgment of non-safety/non-compliance.
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efficiency of the case finding strategies adopted, characteristics of the
catchment areas, varying access to the target population, availability of
local registries, number of staff members dedicated to PF&S case
finding, number of months of active case finding. With regard to the
latter point, while case finding activities were conducted for an average
of 16.4 months, the number of months during which PF&S case finding
was pursued by individual sites varied from 5 to 22 (Table 3). This
heterogeneity has several causes, such as late ethical approval, ad-
ministrative issues, early termination of activities in some centers, and
late engagement of additional sites.
3.3. Characteristics of eligible screenees
The main characteristics of eligible screenees are presented in
Table 4. The mean age was approximately 79 years, with over 70%
women. The vast majority of participants was Caucasian (88%). In this
regard, it should be mentioned that no ethnic minorities were specifi-
cally targeted. The mean BMI was higher than 28 kg/m2, with over one
third of the sample having BMI values ≥30 kg/m2. Candidates were on
average almost completely independent in the basic and instrumental
activities of daily living. As required by the RCT protocol, eligible
screenees were cognitively intact, with a mean MMSE score close to 28.
The mean SARC-F score was nearly 3, which is lower than the cut-off
value suggested for identifying sarcopenia (Malmstrom and Morley,
2013). Similarly, the average calf circumference was approximately
4 cm greater than the cut-point proposed to be indicative of sarcopenia
(Marzetti et al., 2018). Physical performance was significantly im-
paired, as documented by an average score on the SPPB of 6.7 and a 4-
m walk speed of 0.73m/s. The time to complete the 400-m walk test
(8.69min on average) was also indicative of substantial functional
impairment (Vestergaard et al., 2009; Deshpande et al., 2013). With
regard to the sarcopenia component of PF&S, low muscle mass was
more frequently captured by crude aLM in women and by the aLMBMI
criterion in men.
Osteoarthritis was the most prevalent comorbidity among eligible
screenees, followed by cardiovascular conditions, emotional/nervous/
psychiatric problems, diabetes mellitus, chronic lung disease, cancer,
and cerebrovascular accidents. Almost one in two participants reported
at least one fall event occurred in the previous year, and more than one
in ten sustained an injurious fall within the same time-frame.
4. Discussion
In 2013, IMI launched a call seeking for “Developing innovative
therapeutic interventions against physical frailty and sarcopenia as a
prototype geriatric indication”. The SPRINTT project was designed to
provide an objective operationalization of the PF&S condition that
would identify a high-risk population with unmet medical needs
(Marzetti et al., 2015). PF&S was conceptualized as the co-occurrence
of physical function impairment and low muscle mass in the absence of
mobility disability (Cesari et al., 2017). The theoretical framework of
PF&S was built on past landmark experiences in the field and was
mostly inspired by the LIFE study (Pahor et al., 2014) and the FNIH
project (Studenski et al., 2014). One major achievement of the SPRINTT
project has been the identification and initial characterization of PF&S
among older adults living in the community. This challenging task was
accomplished in spite of a number of anticipated and unforeseen dif-
ficulties related to the intrinsic characteristics of the target population
and the transnational and multicultural deployment of the project.
Indeed, several issues were faced related to different national ethical
procedures, country-specific requirements for the use of diagnostic
equipment (e.g., DXA), administrative issues, and case finding chal-
lenges due to the novelty of the PF&S condition. Furthermore, some PF
&S-related attributes were learnt after the beginning of case finding. For
instance, the prevalence of low muscle mass according to the FNIH
criteria is relatively low in older adults with SPPB scores of 8 or 9,
whereas exclusionary conditions are quite common in those
scoring<8 on the SPPB. This latter subgroup is also often reluctant to
engaging in long-term prevention programs such as those proposed in
SPRINTT (Picorelli et al., 2014). Lastly, tools that are commonly re-
commended for the rapid screening of sarcopenia (e.g., SARC-F and calf
circumference) turned out not to be suitable for PF&S case finding.
Through it all, 1566 older persons were found to be eligible for the
RCT across 17 clinical sites. Project advertisement through mass media
was by far the most effective strategy for PF&S case finding. The
screening failure rate was lower than in the LIFE study, with one eli-
gible candidate every 4.3 screenings as opposed to one out 9.1 in LIFE
(Marsh et al., 2013). This reflects a high prevalence of PF&S among
community-dwelling older adults. It should, however, be acknowledged
that the SPRINTT consortium took advantage from the LIFE successes
and shortcomings. The proactive support received by the LIFE study
Fig. 3. Screening and accrual of PF&S candidates during the 22-month case finding period.
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leadership and staff members also allowed SPRINTT to be implemented
without the need of running a pilot trial.
The age and gender distributions of SPRINTT eligible screenees
were comparable to LIFE participants (Pahor et al., 2014). PF&S older
adults are usually overweight, with> 30% of them being obese. This
finding (as well as the high prevalence of concurrent osteoarthritis) is
consistent with the concept of sarcopenic obesity (Roubenoff, 2000),
and adds to a growing literature indicating that excessive adiposity
contributes to physical frailty and functional limitations in advanced
age (Binkley et al., 2013; Porter Starr et al., 2014). Indeed, the adipose
tissue is highly metabolically active and promotes systemic inflamma-
tion and oxidative stress (Hulsegge et al., 2016; Picca et al., 2017). In
addition, excessive adiposity exacerbates the age-associated fat in-
filtration within muscles (Goodpaster et al., 2000), which in turn con-
tributes to muscle dysfunction and frailty (Goodpaster et al., 2001;
Visser et al., 2005). Overweight and obesity are well-known risk factors
for cardiovascular disease. The latter, in turn, may favor the develop-
ment of geriatric syndromes, including frailty (Strandberg et al., 2013;
Atkins et al., 2018).
The prevalence of major comorbid conditions was very similar be-
tween SPRINTT eligible screenees and LIFE participants. Conversely,
functional impairment was more severe among SPRINTT candidates, as
reflected by the lower average SPPB score (6.7 vs. 7.4). This finding is
explained by the higher proportion of participants with SPPB<8 tar-
geted by SPRINTT as opposed to LIFE (80% vs. 45%, respectively). It is
noteworthy that older adults with PF&S were rarely recruited among
people referred to outpatient clinics or hospital services. Most eligible
screenees were indeed gathered among individuals who had not yet
sought any specific medical advice despite their evident functional
impairment. Hence, SPRINTT was able to identify a population of older
adults with clearly unmet clinical needs, at least partly due to under-
estimation of the increased risk profile and the non-referral to clinicians
Fig. 4. Output of PF&S case finding across the 17 SPRINTT
sites. Abbreviations: AstonUni-Birm, Aston University of
Birmingham; CHU-L, University Hospital of Limoges; CHU-
T, University Hospital of Toulouse; CU-Prague, Charles
University; DF, Diabetes Frail Medici Medical Practice; FAU,
Friedrich-Alexander Universität Erlangen-Nürnberg; HUG,
University Hospital of Getafe; HURYC, University Hospital
Ramón y Cajal; JUMC, Jagiellonian University Medical
College; LUH, Lanspitali University Hospital; MedUniGraz,
Medical University of Graz; SL-Opava, Silesians Hospital;
UCSC, Università Cattolica del Sacro Cuore; UH, University
of Helsinki; UniMaas, Maastricht University Medical Center;
UP, University of Parma.
*This site in no longer active.
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for medical advice.
Interestingly, the two alternative FNIH criteria used to identify low
muscle mass (i.e., crude aLM and aLMBMI) showed a gender-specific
distribution, with a greater proportion of men diagnosed with sarco-
penia based on aLMBMI. Low muscle mass was instead more often
captured by unadjusted aLM in women. Preliminary, unpublished
analyses performed on existing data during the SPRINTT preparation
phase showed that aLMBMI detected more instances of sarcopenia in
overweight or obese older adults. Conversely, the crude aLM criterion
was more effective at identifying sarcopenia in individuals with normal
or low BMI. Whether the differential performance of the two FNIH
criteria reflects the existence of gender-specific sarcopenic phenotypes
it will be established through pre-planned secondary analyses at the end
of the project.
In summary, we have described a population of non-disabled older
persons with clear physical impairment specifically linked to muscle
loss. These individuals with unmet medical needs are sufficiently pre-
valent and easy to detect in the community that may represent an ideal
target for pharmacological and non-pharmacological interventions
against sarcopenia and physical frailty. In this context, it is important to
underline the approval that the EMA granted to the SPRINTT metho-
dology, including the rationale underlying the PF&S defining criteria.
5. Conclusion
The global aging of our societies is posing novel and unprecedented
challenges to health and social care systems. The preservation of in-
dependence in late life has therefore become an urgent need to be
achieved through tailored and innovative interventions (Marzetti et al.,
2016). Data presented here show the existence and main characteristics
of a large European sample of older adults with PF&S that represents a
prototypical population with unmet clinical needs. We have
Table 2
Number of screenings per eligible participant (screening failure rate) across the
SPRINTT study sites.
Site name Screening failure rate
Università Cattolica del Sacro Cuore 5.5
IRCCS INRCA 2.8
University of Parma 4.7
University Hospital of Getafe 2.9
University Hospital Ramón y Cajal 2.6
University Hospital of Toulouse 2.7
University Hospital of Limoges 3.7
Charles University 2.6
Silesians Hospital 2.2
Jagiellonian University Medical College 9.2
Friedrich-Alexander Universität Erlangen-Nürnberg 6.6
Maastricht University Medical Center 3.7
University of Helsinki 3.9
Diabetes Frail, Medici Medical Practice 3.9
Aston University of Birminghama 3.3
Medical University of Graz 3.0
Lanspitali University Hospital 5.8
All SPRINTT centers 4.3
a This site is no longer active.
Table 3
Number of months during which PF&S case finding was pursued across the
SPRINTT study sites.
Site name Months of active PF&S case
finding (n)
Università Cattolica del Sacro Cuore 22
IRCCS INRCA 21
University of Parma 12
University Hospital of Getafe 21
University Hospital Ramón y Cajal 21
University Hospital of Toulouse 17
University Hospital of Limoges 20
Charles University 19
Silesians Hospital 17
Jagiellonian University Medical College 22
Friedrich-Alexander Universität Erlangen-
Nürnberg
19
Maastricht University Medical Center 15
University of Helsinki 19
Diabetes Frail, Medici Medical Practice 15
Aston University of Birminghama 5
Medical University of Graz 5
Lanspitali University Hospital 9
Average length of PF&S case finding activities 16.4
a This site in no longer active.
Table 4
Main characteristics of eligible screenees.
Characteristics Eligible screenees
(n=1566)
Demographics
Age (years), mean ± SD 78.9 ± 5.8
Gender (female), n (%) 1119 (71.5)
Race/ethnicity, n (%)
White 1380 (88.1)
Asian 17 (1.1)
African American/black 2 (0.1)
Other 4 (0.3)
Refused/missing 163 (10.4)
Anthropometry
BMI (kg/m2), mean ± SD 28.6 ± 6.0
Calf circumference (cm), mean ± SD 35.0 ± 4.4
Functional ability and cognition
ADL score, mean ± SD 5.6 ± 0.6
IADL score, mean ± SD 7.3 ± 1.2
SARC-F score, mean ± SD 2.9 ± 1.9
MMSE score, mean ± SD 27.9 ± 1.8
PF&S defining parameters
SPPB summary score, mean ± SD 6.7 ± 1.4
Balance score, mean ± SD 2.5 ± 1.0
4-m walk score, mean ± SD 2.8 ± 0.8
Chair-rise score, mean ± SD 1.4 ± 0.8
4-m walk speed (m/s), mean ± SD 0.73 ± 0.19
Time to walk 400m (min), mean ± SD 8.69 ± 2.45
400-m walk speed (m/s), mean ± SD 0.82 ± 0.21
aLM (kg), mean ± SD
Men 21.13 ± 3.52
Women 14.73 ± 2.15
aLMBMI, mean ± SD
Men 0.725 ± 0.083
Women 0.529 ± 0.076
Medical conditions
Any cardiovascular medical history, n (%) 1109 (70.8)
High blood pressure, n (%) 1027 (65.6)
Coronary artery disease, n (%) 138 (8.8)
Congestive heart failure, n (%) 102 (6.5)
Pacemaker, n (%) 44 (2.8)
Chronic lung disease, n (%) 242 (15.5)
Stroke or brain hemorrhage 106 (6.8)
Transient ischemic attack, n (%) 136 (8.7)
Cancer (excluding minor skin cancer), n (%) 217 (13.9)
Diabetes mellitus, n (%) 330 (21.1)
Osteoarthritis, n (%) 1204 (76.9)
Falls(s) in past year, n (%) 694 (44.3)
Injurious fall(s) in past year, n (%) 233 (14.9)
Previous hip fracture(s), n (%) 94 (6.0)
Previous non-femoral fracture(s), n (%) 505 (32.2)
Emotional/nervous/psychiatric problems, n (%) 354 (22.6)
Abbreviations: ADL, activities of daily living; aLM, appendicular lean mass;
aLMBMI, appendicular lean mass to body mass index ratio; BMI, body mass
index; IADL, instrumental activities of daily living; MMSE, Mini Mental State
Examination; PF&S, physical frailty and sarcopenia; SPPB, short physical per-
formance battery.
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demonstrated the feasibility of recruiting a geographically and cultu-
rally heterogeneous population of older community-dwellers at high
risk for disability and other negative health-related events. Key strate-
gies to consider for successful interception of these at-risk older adults
should focus on mass communication methods (e.g., TV broadcasting,
radio, newspapers).
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